Can a patient with brain metastases and hydrocephalus be treated with brain radiotherapy?

Management of Brain Metastases with Concurrent Hydrocephalus

Patients with brain metastases and hydrocephalus can receive radiotherapy, but hydrocephalus must be addressed first through surgical decompression (CSF shunt or endoscopic third ventriculostomy) to prevent life-threatening complications before proceeding with definitive radiation treatment.

Initial Stabilization and Hydrocephalus Management

Hydrocephalus represents a neurosurgical emergency that takes priority over radiotherapy. For patients presenting with obstructive hydrocephalus, compression of the ventricular system, or significant midline shift, surgical decompression is the first emergent priority to prevent brain herniation syndromes and irreversible neurologic injury 1. In patients with brain stem gliomas and hydrocephalus, a cerebrospinal fluid shunt should be offered as standard treatment 1.

Surgical Options for Hydrocephalus

Two primary surgical interventions are available:

• Ventriculoperitoneal shunt (VPS): Used in 65% of cases in recent series, with median overall survival of 79 days post-procedure 2
• Endoscopic third ventriculostomy (ETV): Used in 35% of cases, with median overall survival of 106 days post-procedure 2

Both procedures demonstrate improved survival compared to untreated hydrocephalus (median survival 5.7 months for surgically treated vs. 1.7 months for untreated hydrocephalus) 3. Patients with a single brain metastatic lesion have significantly longer median overall survival than those with multiple metastatic sites (154.5 vs. 67.0 days) 2.

Radiotherapy After Hydrocephalus Treatment

When Radiotherapy Can Proceed

Once hydrocephalus is surgically managed and the patient is stabilized, radiotherapy becomes appropriate:

• For posterior fossa lesions with hydrocephalus: Resecting these lesions resolves mass effect more rapidly than radiosurgery, making surgery followed by stereotactic radiosurgery (S+SRS) the preferred approach 1
• For lesions causing fourth ventricle compression: 96% of patients requiring S+SRS had fourth ventricle compression, compared to 47% in the SRS-alone group 4
• CSF flow studies should be performed before intrathecal chemotherapy in patients with hydrocephalus or large nodules potentially reducing CSF circulation 1

Specific Radiotherapy Considerations

Stereotactic radiosurgery (SRS) is contraindicated in the presence of obstructive hydrocephalus or significant midline shift until these are surgically corrected 1. The factors favoring craniotomy over radiosurgery include:

• Obstructive hydrocephalus present 1
• Midline shift present 1
• Significant mass effect requiring rapid decompression 1
• Tumor size >3 cm 1

After surgical decompression of hydrocephalus, whole brain radiation therapy (WBRT) or focal radiotherapy can be administered 1. For patients with leptomeningeal metastases and symptomatic hydrocephalus requiring ventriculoperitoneal shunt placement, intrathecal pharmacotherapy is not recommended 1.

Treatment Sequencing Algorithm

1. Immediate assessment: Identify hydrocephalus on MRI (fourth ventricle compression, ventricular enlargement) 1
2. Emergent neurosurgical intervention: Place VPS or perform ETV if symptomatic hydrocephalus present 2, 3
3. Medical stabilization: Control cerebral edema with dexamethasone (4-16 mg/day in divided doses) 1
4. Definitive treatment selection:
   • For large posterior fossa lesions (≥4 cc) with hydrocephalus: Surgery followed by SRS (median OS 26 months) 4
   • For smaller lesions after hydrocephalus resolution: SRS alone may be appropriate 1
   • For multiple metastases: WBRT with hippocampal avoidance and memantine 1

Critical Pitfalls to Avoid

Never attempt radiotherapy before addressing symptomatic hydrocephalus, as this can lead to acute neurologic deterioration and death 1. The presence of hydrocephalus indicates significant mass effect that requires mechanical decompression rather than radiation-induced tumor shrinkage, which occurs too slowly to prevent herniation 1.

Do not place prophylactic EVD in all posterior fossa metastasis cases—only 11% develop postoperative hydrocephalus 5. Risk factors warranting prophylactic EVD include: fourth-ventricle-to-tumor-volume ratio ≤0.02, edema-to-tumor-volume ratio ≤0.85, imaging-morphological contact with the fourth ventricle, and multiple intracranial metastases 5.

Interdisciplinary evaluation by neurosurgeons, medical oncologists, and radiation oncologists is essential to facilitate appropriate sequencing of hydrocephalus treatment, systemic therapy, and radiation 2, 6.